

**Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab)
Recombinant Antibody
Catalog # APR10501****Specification**

Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	Q8TDQ0
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	144.9 KDa

Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) - Additional Information**Target/Specificity**

TIM-3 / HAVCR2 / CD366

Endotoxin

< 0.001EU/ µg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) - Protein Information**Name** HAVCR2**Synonyms** TIM3, TIMD3**Function**

Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand (PubMed: [24825777](http://www.uniprot.org/citations/24825777)). Regulates macrophage activation (PubMed: [11823861](http://www.uniprot.org/citations/11823861)). Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance (PubMed: [14556005](http://www.uniprot.org/citations/14556005)). In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK

proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse (PubMed:24337741, PubMed:26492563). In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN (By similarity). Expressed on Treg cells can inhibit Th17 cell responses (PubMed:24838857). Receptor for LGALS9 (PubMed:16286920, PubMed:24337741). Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen- specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis- infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth (By similarity). However, the function as receptor for LGALS9 has been challenged (PubMed:23555261). Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes (By similarity). Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll- like receptors promotes secretion of TNF. In tumor-infiltrating DCs suppresses nucleic acid-mediated innate immune response by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleic acids to endosomes (By similarity). Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9 (PubMed:22323453). In contrast, shown to suppress NK cell-mediated cytotoxicity (PubMed:22383801). Negatively regulates NK cell function in LPS-induced endotoxic shock (By similarity).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Cell junction. Cell membrane.
Note=Localizes to the immunological synapse between CD8+ T-cells and target cells

Tissue Location


Expressed in T-helper type 1 (Th1) lymphocytes. Expressed on regulatory T (Treg) cells after TCR stimulation. Expressed in dendritic cells and natural killer (NK) cells. Expressed in epithelial tissues. Expression is increased on CD4+ and CD8+ T-cells in chronic hepatitis C virus (HCV) infection. In progressive HIV-1 infection, expression is up-regulated on HIV-1-specific CD8 T-cells

Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) - Images



Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody (sabatolimab) is more than 98.49% ,determined by SEC-HPLC.